Methods for inducing human erythroid progenitor cells from hematopoietic stem cells are provided using chemically-defined culture media. Erythroid progenitors generated by the methods include megakaryocyte/erythroid progenitor cells (MEP cells) and CD71+CD235+CD34− erythroid cells, which can be further differentiated into red blood cells. Culture media, isolated cell populations and kits are also provided.

The present description relates to in vitro methods for culturing hematopoietic stem cells (HSCs) under mild hyperthermia conditions (e.g., between 38° C. and 40° C.) in the presence of a pyrimidoindole derivative agonist of hematopoietic stem cell expansion. The combined use of mild hyperthermia and the pyrimidoindole derivative act synergistically to promote expansion of CD34+ HSCs and/or differentiation into progenitor cells (e.g., megakaryocytic progenitors). The present description also relates to in vitro expanded cell populations of HSCs and/or progenitors, as well as uses thereof in therapy (e.g., transplantation).

A method for producing cell aggregates includes culturing cells while suspending the cells in a liquid culture medium comprising a lysophospholipid. A composition includes a lysophospholipid, wherein the composition is a liquid culture medium or a composition added to a liquid culture medium.

The present invention relates to compositions and methods for preparing in vitro models of non-alcoholic fatty liver disease, and more particularly of liver steatosis and fibrosing non-alcoholic steatohepatitis (NASH).

To provide a method for serum-free culture of human cartilage cells and a serum-free culture medium. A method for serum-free culture of cartilage cells, said method comprising: an enzymatic treatment step for treating a human cartilage cell-containing tissue with a protease; an inhibitor-treatment step for, after the enzymatic treatment step, treating the tissue with an inhibitor for the aforesaid protease; and a culture step for, after the inhibitor-treatment step, culturing the tissue in a serum-free culture medium that contains kartogenin and/or SAG, ITS, FGF2 and hydrocortisone. A serum-free culture medium for culturing cartilage cells, said serum-free culture medium containing kartogenin and/or SAG, ITS, FGF2 and hydrocortisone.

Provided herein, inter alia, are compositions and methods for culturing mammalian cells. In certain aspects, the composition is a medium containing one or more of a lithium ion source, one or more fatty acids, and/or ethanol. Use of any of the cell culture media described herein to culture cells that have been genetically engineered to produce one or more recombinant polypeptides (for example, antibodies) can result in increased titers, a more favorable glycosylation profile, and/or modulated (e.g. decreased) amounts of high and low molecular weight species, and/or modulated (e.g. decreased) amounts of acidic or basic charge variants, compared to cells cultured in a medium that does not contain one or more of a lithium ion source, one or more fatty acids, and/or ethanol.

A method for treating an oral condition of a subject by grafting cultured tissue constructs to the oral tissue. The cultured tissue constructs comprise cultured cells and endogenously produced extracellular matrix components without the requirement of exogenous matrix components or network support or scaffold members. Some tissue constructs of the invention are comprised of multiple cell layers or more than one cell type. The tissue constructs of the invention have morphological features and functions similar to tissues their cells are derived and their strength makes them easily handleable. Preferred cultured tissue constructs of the invention comprise cells derived from human tissue.

Therapeutics comprising Cells and methods of creating enhanced human Placenta Mesenchymal Stem Cells (hPMSCs) comprising culturing the hPMSCs with cholesterol for one of between 24 and 96 hours and between 48 and 72 hours. Therapeutics comprising microparticles and methods of creating enhanced microparticles from hPMSCs comprising culturing the hPMSCs with cholesterol for one of between 24 and 96 hours and between 48 and 72 hours, and then separating the enhanced microparticles from the hPMSCs. Therapeutics comprising exosomes and methods of creating enhanced exosomes from hPMSCs comprising culturing the hPMSCs with cholesterol for one of between 24 and 96 hours and between 48 and 72 hours, and then separating the enhanced microparticles from the hPMSCs. Therapeutic comprising extracellular vesicles and methods of creating enhanced EVs from hPMSCs comprising culturing the hPMSCs with cholesterol for one of between 24 and 96 hours and between 48 and 72 hours.

The present invention provides methods for increasing cell culture performance through the use of chemically defined feed media (CDFM). In particular, the present invention provides methods for the use of surfactants as supplements to CDFM to allow for higher concentrations of media components and thereby result in increased cell culture performance.

Described herein are methods for enhancing engraftment of hematopoietic stem and progenitor cells using farnesyl compounds identified using a zebrafish model of hematopoietic cell engraftment. The compounds can be used to treat hematopoietic stem cells ex vivo prior to transplantation of the cells. Alternatively, the compounds can be administered to an individual undergoing cell transplantation.